
FDA approves first immunotherapy for advanced rectal cancer
The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly). The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer. Patients with locally advanced rectal cancer often receive chemotherapy… Read More










